Unknown

Dataset Information

0

Prevalence and Impact of Atrial Fibrillation in Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis.


ABSTRACT:

Background

In patients with COVID-19, cardiovascular complications are common and associated with poor prognosis. Among these, an association between atrial fibrillation (AF) and COVID-19 has been described; however, the extent of this relationship is unclear. The aim of this study is to investigate the epidemiology of AF in COVID-19 patients and its impact on all-cause mortality.

Methods

A systematic review and meta-analysis were performed and reported according to PRISMA guidelines, and a protocol for this study was registered on PROSPERO (CRD42021227950). PubMed and EMBASE were systematically searched for relevant studies. A random-effects model was used to estimate pooled odds ratios (OR) and 95% confidence intervals (CI).

Results

Overall, 31 studies were included in the analysis, with a total number of 187,716 COVID-19 patients. The prevalence of AF was found to be as high as 8% of patients with COVID-19 (95% CI: 6.3-10.2%, 95% prediction intervals (PI): 2.0-27.1%), with a high degree of heterogeneity between studies; a multiple meta-regression model including geographical location, age, hypertension, and diabetes showed that these factors accounted for more than a third of the heterogeneity. AF COVID-19 patients were less likely to be female but more likely older, hypertensive, and with a critical status than those without AF. Patients with AF showed a significant increase in the risk of all-cause mortality (OR: 3.97, 95% CI: 2.76-5.71), with a high degree of heterogeneity. A sensitivity analysis focusing on new-onset AF showed the consistency of these results.

Conclusions

Among COVID-19 patients, AF is found in 8% of patients. AF COVID-19 patients are older, more hypertensive, and more likely to have a critical status. In COVID-19 patients, AF is associated with a 4-fold higher risk of death. Further studies are needed to define the best treatment strategies to improve the prognosis of AF COVID-19 patients.

SUBMITTER: Romiti GF 

PROVIDER: S-EPMC8200114 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC8548384 | biostudies-literature
| S-EPMC9638315 | biostudies-literature
| S-EPMC10480662 | biostudies-literature
| S-EPMC8483996 | biostudies-literature
| S-EPMC7968150 | biostudies-literature
| S-EPMC8423751 | biostudies-literature
| S-EPMC7852167 | biostudies-literature
| S-EPMC7920817 | biostudies-literature
| S-EPMC9978404 | biostudies-literature
| S-EPMC8055982 | biostudies-literature